Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00580385 · ClinicalTrials.gov registry record · NA

Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors

A NA study of Osteosarcoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
NA
Development phase
763
Enrollment target
1
Study location

NCT00580385: Active NA study of Osteosarcoma, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00580385 is a NA study of Osteosarcoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 763 participants, above the 285-participant average among 46 other Osteosarcoma trials with a reported enrollment target (168% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00580385, a NA study of Osteosarcoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
763 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate tumors in the laboratory to determine how and why they respond, or fail to respond to different drug therapies. This study will also investigate why high pressure develops within tumors and how this affects how well drugs work. We will also take blood samples before and/or after your procedure to measure biochemical factors that may help us predict the behavior of osteogenic sarcoma and other solid tumors.

Conditions Studied

Interventions

  • OTHER Tissue Procurement

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 763 participants
Start Date 1997-08
Est. Completion 2026-08
Phase NA
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT00580385 still lists

NCT00580385 is an interventional study that assigns participants to a tested intervention. The registered 763 participants enrollment target is mid-sized for trials with a published cap, above the 285-participant average among 46 other Osteosarcoma trials with a reported enrollment target (168% higher).

The record links to 1 condition, with Osteosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Tissue Procurement is the first listed.

NCT00580385 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00580385 about?

NCT00580385 is a clinical study titled "Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors". The purpose of this study is to investigate tumors in the laboratory to determine how and why they respond, or fail to respond to different drug therapies. This study will also investigate why high pressure develops within tumors and how this affects how well drugs work. We will also take blood samp...

What is the current status of trial NCT00580385?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 763 participants. The study started on 1997-08. Estimated completion is 2026-08.

What conditions does trial NCT00580385 study?

This clinical trial studies the following conditions: Osteosarcoma.

What interventions are being tested in trial NCT00580385?

The interventions under investigation include: Tissue Procurement (OTHER).

Who is sponsoring clinical trial NCT00580385?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00580385 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteosarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00580385's enrollment target sits among peer trials

763 2nd of 46 the highest of 46 other Osteosarcoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Osteosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04578665 · 764 participants · NA

    Human-like Robotic Controllers for Enhanced Motor Learning

  • NCT05579366 · 764 participants · Phase 1

    Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • NCT06419374 · 762 participants · Phase 3

    A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

  • NCT03789552 · 765 participants · Phase 3

    Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00580385, the US trial registry maintained by the National Library of Medicine. NCT00580385 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.